Micronutrient concentrations and subclinical atherosclerosis in adults with HIV

American Journal of Clinical Nutrition

Volumn 92, Issue 1, 2010, Pages 266-267

  Traber, Maret G ^a   Frei, Balz ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CALCIUM; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ALPHA TOCOPHEROL TRANSFER PROTEIN; ALPHA-TOCOPHEROL TRANSFER PROTEIN; BIOLOGICAL MARKER; CARRIER PROTEIN; TRACE ELEMENT;

ANTIOXIDANT ACTIVITY; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CANCER MORTALITY; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; COHORT ANALYSIS; CORONARY ARTERY; DIABETES MELLITUS; DISEASE COURSE; FOAM CELL; FOLLOW UP; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INTERNAL CAROTID ARTERY; LETTER; MACROPHAGE; MORTALITY; NUTRIENT CONCENTRATION; SCORING SYSTEM; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN BLOOD LEVEL; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION; ADULT; ALPHA TOCOPHEROL DEFICIENCY; BLOOD; CAROTID ARTERY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTIMA; METABOLISM; NOTE; PATHOLOGY; TUNICA MEDIA;

ADULT; ALPHA-TOCOPHEROL; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CAROTID ARTERIES; CARRIER PROTEINS; COHORT STUDIES; DISEASE PROGRESSION; FOAM CELLS; HIV INFECTIONS; HUMANS; MACROPHAGES; MICRONUTRIENTS; TUNICA INTIMA; TUNICA MEDIA; VITAMIN E; VITAMIN E DEFICIENCY;

EID: 77954578408     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.2010.29608     Document Type: Letter

References (10)

1. Falcone EL, Mangili A, Tang AM, et al. Micronutrient concentrations and subclinical atherosclerosis in adults with HIV. Am J Clin Nutr 2010;91:1213-9.
2. Wang X, Liao D, Lin PH, Yao Q, Chen C. Highly active antiretroviral therapy drugs inhibit in vitro cholesterol efflux from human macrophage-derived foam cells. Lab Invest 2009;89:1355-63.
3. Traber MG. Vitamin E regulatory mechanisms. Annu Rev Nutr 2007;27:347-62.
4. Ford ES, Sowell A. Serum alpha-tocopherol status in the United States population: findings from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 1999;150:290-300.
5. Wright ME, Lawson KA, Weinstein SJ, et al. Higher baseline serum concentrations of vitamin E are associated with lower total and causespecific mortality in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Am J Clin Nutr 2006;84:1200-7.
6. Devaraj S, Adams-Huet B, Fuller CJ, Jialal I. Dose-response comparison of RRR-alpha-tocopherol and all-racemic alpha-tocopherol on LDL oxidation. Arterioscler Thromb Vasc Biol 1997;17:2273-9.
7. Diaz MN, Frei B, Vita JA, Keaney JFJ. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997;337:408-16.
8. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:154-60.
9. Levy AP, Gerstein HC, Miller-Lotan R, et al. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care 2004;27:2767.
10. Milman U, Blum S, Shapira C, et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol 2008;28:341-7.